Tonic Motor Activation (TOMAC) for Restless Legs Syndrome — Coverage Criteria
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Policy governing coverage determinations for bilateral peroneal nerve stimulation (TOMAC) to treat primary restless legs syndrome (RLS) refractory to medication for Blue Cross Blue Shield - Rhode Island members.
No material clinical or coverage changes in this revision.
Coverage Determination and Criteria
Coverage determination for TOMAC as a treatment for RLS
Covered when ALL of the following are met:
Policy states TOMAC is indicated clinically only for moderate-to-severe primary RLS refractory to pharmacologic treatment, but coverage is denied based on evidence assessment.
TOMAC is not a first-line therapy; it is intended for cases refractory to standard treatments such as iron supplementation, gabapentinoids, and behavioral measures.
Clinical pathway describes TOMAC as indicated only after failure of pharmacologic treatment.
Use of HCPCS codes A4544 and E0743 for bilateral peroneal nerve stimulation (TOMAC) is listed as not covered for Medicare Advantage plans and not medically necessary for Commercial products.
For Commercial products, TOMAC for medication-refractory restless legs syndrome is considered not medically necessary because the evidence is insufficient to demonstrate improvement in net health outcome. The available literature includes randomized controlled trials, nonrandomized studies, and a systematic review/meta-analysis that showed some symptom and sleep quality benefits versus sham but were limited by small sample sizes, short follow-up, potential unblinding, and lack of long-term randomized data; these limitations prevent concluding durable clinical benefit.
Billing and Coding
Provider Responsibilities and Billing Actions
Prior Authorization
Prior authorization is not applicable for this policy.
Therapy Sequencing
TOMAC (transcutaneous osseous magnetic stimulation) is not a first-line therapy. It is indicated only for moderate-to-severe primary restless legs syndrome (RLS) that is refractory to pharmacologic therapy; first-line options include iron supplementation, gabapentinoids, and lifestyle modifications.
Verify Benefits and Eligibility
Verify benefits and eligibility prior to providing services. Coverage may vary by contract; refer to the member's Evidence of Coverage / Subscriber Agreement or contact the provider call center for member-specific information.
Billing Denial Risk for Listed Codes
Billing denial risk: the following codes will be considered not covered / not medically necessary for this indication and may be denied if billed for external lower extremity nerve stimulation for RLS.
Clinical Background
Restless legs syndrome (RLS) is a neurologic disorder characterized by an uncontrollable urge to move the legs, often accompanied by uncomfortable sensations and associated sleep disturbance. Patients commonly experience periodic limb movements during sleep, and standard management emphasizes pharmacologic therapies (for example, alpha-2-delta ligands or dopaminergic agents), iron repletion when indicated, and behavioral measures prior to consideration of device-based interventions such as TOMAC.
Key Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.